Avinger (AVGR) Reports Q4 Loss Per Share of $33.62, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Avinger, Inc. Announces Fourth Quarter and Full Year 2014 Results
March 12, 2015 4:05 PM EDTREDWOOD CITY, Calif., March 12, 2015 (GLOBE NEWSWIRE) -- Avinger, Inc., (Nasdaq: AVGR) a developer and manufacturer of image-guided, catheter-based systems for the treatment of peripheral arterial disease (PAD) and pioneer of the lumivascular approach to treating vascular disease, today reported financial results for the fourth quarter and year ended December 31, 2014.
Recent Highlights
Completed enrollment in VISION, a 133-patient clinical trial designed to evaluate the safety and efficacy of Pantheris, Avinger's image-guided atherectomy device, which allows physicians to precisely remove arterial plaque in PAD patients. Completed an initial public offering of five million... More